Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Gains from Sales and Divestitures (2016 - 2020)

Historic Gains from Sales and Divestitures for Myriad Genetics (MYGN) over the last 6 years, with Q2 2020 value amounting to $900000.0.

  • Myriad Genetics' Gains from Sales and Divestitures rose 1250.0% to $900000.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $900000.0, marking a year-over-year increase of 1250.0%. This contributed to the annual value of $900000.0 for FY2020, which is 1250.0% up from last year.
  • Myriad Genetics' Gains from Sales and Divestitures amounted to $900000.0 in Q2 2020, which was up 1250.0% from $900000.0 recorded in Q1 2020.
  • Myriad Genetics' Gains from Sales and Divestitures' 5-year high stood at $900000.0 during Q4 2019, with a 5-year trough of $400000.0 in Q1 2016.
  • Its 5-year average for Gains from Sales and Divestitures is $620000.0, with a median of $700000.0 in 2017.
  • Per our database at Business Quant, Myriad Genetics' Gains from Sales and Divestitures surged by 195128.21% in 2016 and then changed by 0.0% in 2017.
  • Myriad Genetics' Gains from Sales and Divestitures (Quarter) stood at $400000.0 in 2016, then skyrocketed by 75.0% to $700000.0 in 2017, then changed by 0.0% to $700000.0 in 2018, then rose by 28.57% to $900000.0 in 2019, then changed by 0.0% to $900000.0 in 2020.
  • Its last three reported values are $900000.0 in Q2 2020, $900000.0 for Q1 2020, and $900000.0 during Q4 2019.